Composition for injectable preparation for reducing skin wrinkles, improving elasticity, and regenerating skin, and use thereof

Abstract

The present invention relates to a composition for an injectable preparation for reducing skin wrinkles, enhancing elasticity, and regenerating the skin. The composition is formed by mixing hyaluronic acid, botulinum toxin, polydeoxyribonucleotide, placental extract, poly-D,L-lactic acid, adenosine, epidermal growth factor, vitamin C (ascorbic acid), tranexamic acid, and normal saline in an optimal ratio. Each ingredient contributes to improving the overall health of the skin through skin moisturization, wrinkle reduction, elasticity enhancement, anti-inflammatory and antioxidant effects, and also effectively alleviates signs of skin aging, maintains stability even if stored long term, and minimizes pain or discomfort during injection, thereby increasing user convenience.

Description

Injectable composition for improving wrinkles, elasticity, and skin regeneration, and the use thereof

[0001] The present invention relates to an injectable composition for improving wrinkles, elasticity, and skin regeneration, and its uses. The injectable composition of the present invention can be utilized to improve wrinkles and elasticity more quickly and effectively through skin moisturization, collagen production, activation of skin regeneration, and anti-inflammatory and antioxidant effects.

[0002] In modern society, wrinkles and a decline in skin elasticity are natural phenomena that occur with aging, yet many people experience cosmetic dissatisfaction as a result. In particular, decreased skin elasticity and deepening wrinkles not only affect an individual's appearance but can also lead to psychological issues such as a loss of self-confidence. These skin problems are exacerbated not only by aging but also by various external factors such as UV exposure, environmental pollution, stress, and smoking.

[0003] To address this, various cosmetics, dermatological treatments, and procedures are being developed; however, in many cases, they offer only short-term effects or struggle to achieve sustainable skin improvement, and some treatments face limitations in widespread use due to high costs and invasiveness. In particular, existing cosmetic injectables focus on specific functions such as wrinkle reduction or skin elasticity enhancement, falling short of providing comprehensive skin improvement effects that include skin regeneration and anti-inflammatory benefits.

[0004] Injectable treatments are gaining attention as a therapeutic method for skin regeneration and wrinkle improvement. Injectables overcome the limitations of existing topical cosmetics or indirect treatments by directly delivering active ingredients to the deep layers of the skin, such as the dermis and subcutaneous layer. While topical cosmetics struggle to penetrate the skin barrier and offer only superficial effects, injectables can induce fundamental changes—such as skin cell regeneration, collagen production, and wrinkle improvement—by directly delivering various ingredients. Furthermore, because they allow for the precise and uniform injection of ingredients into localized areas, they are effective for treating wrinkles or improving skin in specific regions.

[0005] However, existing injectable compositions tend to rely on the effects of a single component or focus on specific effects, which limits their ability to achieve comprehensive skin improvement. Furthermore, due to a lack of anti-inflammatory and antioxidant effects necessary for skin damage repair—such as inflammation suppression and free radical scavenging—it is difficult to expect long-term skin improvement.

[0006] Therefore, the present invention aims to develop an injectable composition capable of providing both anti-inflammatory and antioxidant effects on the skin by overcoming the limitations of existing injectables and including various ingredients for improving skin wrinkles, enhancing elasticity, and regenerating skin in an optimal mixing ratio. The composition of the present invention comprises hyaluronic acid, botulinum toxin, polydeoxyribonucleotide, placenta extract, and poly-d,l-lactic acid, and furthermore, by combining adenosine, epidermal growth factor, and other antioxidant components, the overall skin improvement effect can be maximized. Through this, the present invention can provide a safer and more sustainable skin improvement effect than existing injectables.

[0007] The objective of the present invention is to provide an injectable composition for improving wrinkles, elasticity, and skin regeneration.

[0008] To achieve the above objectives, the present invention provides an injectable composition for improving wrinkles, elasticity, and skin regeneration comprising hyaluronic acid, botulinum toxin, polydeoxyribonucleotide, placenta extract, poly-d,l-lactic acid, and normal saline.

[0009] In one embodiment of the present invention, the "composition" may further include adenosine, epidermal growth factor, and vitamin C (ascorbic acid) as active ingredients, but is not limited thereto.

[0010] In one embodiment of the present invention, the "composition" may be characterized by being prepared by mixing 0.5 to 0.7 cc of hyaluronic acid, 6 to 7 IU of botulinum toxin, 0.05 to 0.12 cc of polydeoxyribonucleotide, 0.05 to 0.12 cc of placenta extract, and 0.01 to 0.05 cc of poly-d,l-lactic acid with 0.1 cc to 0.2 cc of normal saline, based on 1 cc of an injectable composition, but is not limited thereto.

[0011] In one embodiment of the present invention, the "composition" may be characterized by being prepared by mixing 0.5 to 0.7 cc of hyaluronic acid, 6 to 7 IU of botulinum toxin, 0.05 to 0.12 cc of polydeoxyribonucleotide, 0.05 to 0.12 cc of placenta extract, 0.01 to 0.05 cc of poly-d,l-lactic acid, 0.01 to 0.05 cc of adenosine, 0.01 to 0.03 cc of epidermal growth factor, and 0.01 to 0.05 cc of vitamin C with 0.1 cc to 0.2 cc of normal saline, based on 1 cc of an injectable composition. It is not limited to this.

[0012] In one embodiment of the present invention, the "composition" may further include tranexamic acid, but is not limited thereto.

[0013] The present invention relates to an injectable composition for skin regeneration and wrinkle improvement and its use. The injectable composition of the present invention can be utilized to improve the skin more quickly and continuously through skin wrinkle improvement, elasticity enhancement, cell regeneration promotion, anti-inflammatory and antioxidant effects. Furthermore, hyaluronic acid, botulinum toxin, polydeoxyribonucleotide, placenta extract, poly-d,l-lactic acid, and additionally included adenosine, epidermal growth factor, and antioxidant components in the injectable composition of the present invention exhibit synergistic effects through interaction at an optimal mixing ratio, and can induce skin regeneration and wrinkle and elasticity improvement effects without side effects.

[0014] In particular, the injectable composition of the present invention can provide a sustainable skin improvement effect by inducing not only short-term effects but also long-term collagen production, and the composition has excellent stability during manufacturing and storage, and maintains physical and chemical stability even against external stimuli (e.g., temperature changes or vibration).

[0015] Hereinafter, the present invention will be described in detail with reference to the attached drawings and embodiments thereof. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalent scope interpreted therefrom.

[0016] Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0017] Throughout this specification, '%' used to indicate the concentration of a particular substance is (w / w) % for solid / solid, (w / v) % for solid / liquid, and (v / v) % for liquid / liquid, unless otherwise noted.

[0018] In one aspect, the present invention provides an injectable composition for improving wrinkles, elasticity, and skin regeneration.

[0019] The injectable composition of the present invention for improving wrinkles, elasticity, and skin regeneration can be injected densely into the subcutaneous fat layer at intervals of 1 to 1.5 cm.

[0020] The injectable composition of the present invention may additionally include an adjuvant in addition to the active ingredient. Any adjuvant known in the art may be used without limitation, but, for example, Freund's complete or incomplete adjuvant may be further included to increase its functionality.

[0021] The injectable composition according to the present invention may be prepared in a form in which an active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the injectable composition of the present invention are not limited to these, but may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0022] The injectable compositions of the present invention can each be formulated into the form of sterile injectable solutions according to conventional methods and used.

[0023] When formulating, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, humectants, disintegrants, and surfactants. In addition, lubricants such as magnesium stearate and talc may be used in addition to simple excipients. Preparations for parenteral administration, such as injectable compositions, may include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As water-insoluble solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Tween 61, cacao oil, laurin oil, glycerogelatin, etc. may be used. Furthermore, the injectable composition according to the present invention may be administered to an individual by injection into the subcutaneous fat layer.

[0024] The dosage of the injectable composition according to the present invention is selected by taking into consideration the individual's age, weight, gender, physical condition, etc. It is obvious that the concentration of the active ingredient included in the injectable composition can be selected in various ways depending on the subject, and the injectable formulation may use a fatty acid such as oleic acid.

[0025] In one aspect, the injectable composition for wrinkle, elasticity improvement and skin regeneration of the present invention may be prepared by mixing hyaluronic acid, botulinum toxin, polydeoxyribonucleotide, placenta extract, and poly-d,l-lactic acid in normal saline.

[0026] The roles performed by each of the above components in the injectable composition for wrinkle reduction, elasticity improvement, and skin regeneration are as follows.

[0027] The "hyaluronic acid" used in this invention is a major component of the dermal layer of the skin, and plays a role in maximizing skin hydration and strengthening elasticity through its excellent water-binding capacity. Specifically, it supplies moisture to skin prone to dryness after lipolysis or skin procedures to promote the regeneration of damaged skin tissue and restore skin volume, thereby helping to maintain natural elasticity and a smooth skin texture. Furthermore, it supports the healing process of skin cells and contributes to improving skin condition after injection and enhancing the effect of wrinkle reduction.

[0028] The component "Botulinum Toxin" used in the present invention inhibits the release of neurotransmitters to relieve muscle contraction and plays an effective role in improving wrinkles and enhancing skin elasticity. Specifically, it smooths the skin surface by alleviating wrinkles formed by repetitive muscle movements, such as facial expression lines, and contributes to preventing wrinkle formation by relieving muscle tension in the deep layers of the skin. Furthermore, it increases skin elasticity and helps maintain a younger and more vibrant skin condition after the procedure. In addition, Botulinum Toxin contributes to enhancing the skin improvement effect by combining with other components.

[0029] The component "Polydeoxyribonucleotide" used in this invention is an effective substance for promoting cell regeneration and aiding in the repair of damaged tissue, playing a role in activating the skin regeneration and healing processes. Specifically, Polydeoxyribonucleotide extracted from salmon or trout DNA induces the growth and differentiation of skin cells, thereby accelerating the recovery rate of damaged skin tissue and contributing to the stabilization of skin conditions by suppressing inflammatory responses. Furthermore, Polydeoxyribonucleotide enhances skin elasticity and provides long-term skin improvement effects, such as wrinkle reduction, helping to maintain the skin in a healthy and vibrant state after injection.

[0030] The "placenta extract" used in this invention is a bioactive substance extracted from the placenta that plays a key role in helping to improve the skin through cell regeneration and nutrient supply. Specifically, the placenta extract contains abundant bioactive components that promote skin cell regeneration, repair damaged tissues, and enhance skin elasticity and moisture retention. Furthermore, the placenta extract provides antioxidant and anti-inflammatory effects to alleviate skin irritation and inflammation, stabilize the skin condition after injection, and contribute to enhancing the effect of natural and healthy skin improvement.

[0031] The placenta extract according to the present invention comprises an extract obtained from an ingestible placenta, and the extract may be obtained using extraction and separation methods known in the art. Additionally, a commercially available product (e.g., Biocatarrhiza placenta APF(SW)(M-PE-APF)) may be used as the placenta extract. The "extract" defined in the present invention is a placenta extracted using a suitable solvent, and includes, for example, crude extracts, extracts soluble in polar solvents, or extracts soluble in non-polar solvents. As a suitable solvent for preparing the above placenta extract, any organic solvent permitted in pharmaceuticals or cosmetics may be used, and water or organic solvents may be used, but are not limited thereto, various solvents such as purified water, alcohols having 1 to 4 carbon atoms including methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, and cyclohexane may be used alone or in combination. As an extraction method, any one of the following may be selected and used: water bath extraction, hot water extraction, cold maceration extraction, reflux extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, or pressing. In addition, the desired extract may undergo a conventional fractionation process and may be purified using a conventional purification method.

[0032] There are no limitations on the method for preparing the extract of the present invention, and any known method may be used. For example, the extract included in the composition of the present invention may be prepared in a powder state by additional processes such as spray drying, vacuum distillation, or freeze-drying, using a primary extract obtained by the aforementioned hot water extraction or solvent extraction method. Additionally, a further purified fraction may be obtained from the primary extract using various chromatographic methods such as silica gel column chromatography, thin layer chromatography, or high performance liquid chromatography. Accordingly, in the present invention, the term "extract" encompasses all extracts, fractions, and purified products obtained at each stage of extraction, fractionation, or purification, as well as their dilutions, concentrates, or dried products.

[0033] The component "Poly-d,l-lactic acid" used in this invention is a biodegradable polymer that stimulates collagen production in the deep layers of the skin, providing long-term skin elasticity enhancement and wrinkle improvement effects. Specifically, Poly-d,l-lactic acid gradually decomposes after being injected into the skin; during this process, it stimulates skin cells to induce collagen synthesis and strengthens the skin structure to improve elasticity. Furthermore, Poly-d,l-lactic acid helps restore skin volume and maintain a smooth and elastic skin condition long-term after injection. In addition, Poly-d,l-lactic acid has high biocompatibility, resulting in a low risk of side effects, and contributes to maximizing skin improvement effects when combined with other ingredients.

[0034] Throughout this specification, the units of specific substances are indicated as “mg” for solids, “cc” for liquids, and “units (IU)" for botulinum toxin.

[0035] The composition of the present invention is characterized by being prepared by mixing 0.5 to 0.7 cc of hyaluronic acid, 6 to 7 IU of botulinum toxin, 0.05 to 0.12 cc of polydeoxyribonucleotide, 0.05 to 0.12 cc of placenta extract, and 0.01 to 0.05 cc of poly-d,l-lactic acid with 0.1 cc to 0.2 cc of normal saline, based on 1 cc of the injectable composition.

[0036] When the injectable composition is used within the above ratio range, skin moisturization, wrinkle improvement, regeneration, and elasticity enhancement can be achieved simultaneously through the synergistic effect between each component, so it can be utilized as an innovative injectable for skin improvement that combines safety and efficacy.

[0037] In one aspect, the injectable composition of the present invention for improving wrinkles, elasticity, and skin regeneration may further include adenosine, epidermal growth factor, and vitamin C (ascorbic acid) as active ingredients.

[0038] The component "Adenosine" used in this invention is a key ingredient in cellular energy metabolism and is a substance that plays an effective role in skin regeneration and wrinkle improvement. Specifically, Adenosine contributes to increasing skin elasticity and alleviating wrinkles by activating skin cell metabolism to promote the production of collagen and elastin. Furthermore, Adenosine provides an anti-inflammatory effect that suppresses inflammatory responses and soothes the skin, helping to stabilize the skin condition after injection and maintain healthier, more vibrant skin. Due to its excellent stability and efficacy, it plays an important role in cosmetic and skin improvement compositions.

[0039] The "Epidermal Growth Factor" used in this invention is a protein that promotes cell growth and regeneration, playing a key role in skin regeneration and damage repair. Specifically, the Epidermal Growth Factor binds to growth factor receptors on the surface of skin cells to activate cell division and regeneration, inducing the recovery of damaged tissue and an increase in skin thickness. Through this, it provides effects such as wrinkle improvement and elasticity enhancement, and exhibits excellent efficacy in cell repair processes, particularly in skin wound healing. Furthermore, the Epidermal Growth Factor keeps the skin healthier and more vibrant, and can maximize skin regeneration and improvement effects when combined with other ingredients.

[0040] The component "Vitamin C (Ascorbic Acid)" used in this invention is a powerful antioxidant that protects the skin from free radicals and plays an important role in skin regeneration and wrinkle improvement. Specifically, Vitamin C (Ascorbic Acid) reduces oxidative stress in skin cells to prevent cell damage and promotes collagen production, thereby providing skin elasticity and wrinkle improvement effects. Furthermore, it exhibits a whitening effect by evening out skin tone and alleviating pigmentation, and contributes to improving skin condition after injection and maintaining the skin in a healthier and brighter state. By applying special stabilization technology, Vitamin C (Ascorbic Acid) can be utilized more effectively in the composition.

[0041] The composition of the present invention is characterized by being prepared by mixing 0.5 to 0.7 cc of hyaluronic acid, 6 to 7 IU of botulinum toxin, 0.05 to 0.12 cc of polydeoxyribonucleotide, 0.05 to 0.12 cc of placenta extract, 0.01 to 0.05 cc of poly-d,l-lactic acid, 0.01 to 0.05 cc of adenosine, 0.01 to 0.03 cc of epidermal growth factor, and 0.01 to 0.05 cc of vitamin C with 0.1 cc to 0.2 cc of normal saline, based on 1 cc of the injectable composition.

[0042] If the content of the hyaluronic acid is below the above range, there is a concern that the skin's moisturizing effect and volume-maintaining ability may decrease, resulting in insufficient wrinkle improvement and elasticity enhancement effects. This may lead to dry skin and problems with maintaining skin elasticity after the procedure. On the other hand, if it exceeds the above range, the viscosity of the injectable becomes excessively high, which may cause the syringe to clog during the injection process and increase the likelihood of the patient experiencing pain and discomfort during the injection, which may be undesirable.

[0043] If the content of the above-mentioned botulinum toxin is below the above range, the wrinkle-reducing effect and the skin elasticity-enhancing effect are significantly reduced, making it difficult to obtain the desired results after the procedure. This may result in insufficient muscle relaxation, causing expression lines to persist or the improvement effect to be minimal. Conversely, if it exceeds the above range, it may be undesirable as there is a possibility of side effects such as unnatural facial expressions or abnormal muscle paralysis due to excessive muscle relaxation.

[0044] If the content of the above polydeoxyribonucleotide is below the above range, the cell regeneration and tissue repair effects are insufficient, which may slow down the healing speed of the damaged skin area and limit the improvement of the skin condition after the procedure. Conversely, if it exceeds the above range, it may be undesirable as there is a possibility of inflammatory reactions due to cell overproliferation or abnormal proliferation of skin tissue.

[0045] If the content of the above placenta extract is below the above range, the skin cell regeneration and nutrient supply effects may not be sufficiently exerted, and the skin repair and elasticity improvement effects may be reduced. On the other hand, if it exceeds the above range, there is a possibility that the viscosity of the composition may increase or local irritation may occur at the treatment site, which may cause discomfort to the patient and may not be desirable.

[0046] If the content of the above-mentioned poly-d,l-lactic acid is below the above range, the collagen-generating effect is negligible, making it difficult to expect improvements in skin elasticity and wrinkles after the procedure. Conversely, if it exceeds the above range, the molecular weight increases, the particle size becomes larger, and there is a higher likelihood of causing inflammatory reactions and pain at the injection site, which may be undesirable. In addition, an excessive content may have a negative impact on the human body during the decomposition process.

[0047] If the content of the adenosine is below the above range, the wrinkle improvement and anti-inflammatory effects may not be sufficiently exerted, and the rate of improvement in the skin condition after the procedure may be slow. Conversely, if it exceeds the above range, cell metabolism may be excessively activated, which may be undesirable as it may cause skin hypersensitivity reactions or induce inflammation.

[0048] If the content of the above-mentioned Epidermal Growth Factor is below the above range, the regenerative and damage repair effects of skin cells are limited, and there is a concern that wound healing and tissue restoration may be delayed after the procedure. Conversely, if it exceeds the above range, excessive cell proliferation may occur, potentially leading to an imbalance within the skin tissue or unexpected side effects, which may be undesirable.

[0049] If the content of Vitamin C (Ascorbic Acid) is below the above range, the antioxidant and whitening effects are negligible, so protection against skin damage and tone improvement may not be sufficiently achieved. Conversely, if it exceeds the above range, the oxidative stability of Vitamin C is reduced, which may be undesirable as it may cause the composition to deteriorate easily or lead to local irritation and inflammatory reactions at the injection site.

[0050] In one aspect, the injectable composition of the present invention for improving wrinkles, elasticity and skin regeneration may further include tranexamic acid as an active ingredient.

[0051] The component "Tranexamic Acid" used in the present invention helps alleviate melasma and pigmentation by blocking the melanin production pathway through the inhibition of the conversion of plasminogen to plasmin, and specifically, has whitening and pigmentation improvement effects. In addition, it contributes to the improvement of overall skin tone by reducing inflammatory responses in the skin through anti-inflammatory action, and due to these characteristics, it can be utilized in injectable compositions for effects such as improving skin wrinkles, promoting elasticity, and whitening.

[0052] The present invention will be explained in more detail below through examples. However, the above examples and experimental examples are presented as illustrative examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited by this. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalent scope interpreted therefrom.

[0053] <Preparation Example> Preparation of an injectable composition

[0054] To prepare the injectable composition for wrinkle, elasticity improvement, and skin regeneration according to the present invention, it was formulated as follows.

[0055] Basically, each component was mixed into Normal Saline. The components used in the above mixture are Hyaluronic Acid, Botulinum Toxin, Polydeoxyribonucleotide, Placenta Extract, Poly-d,l-Lactic Acid, Adenosine, Epidermal Growth Factor, Vitamin C (Ascorbic Acid), and Tranexamic Acid.

[0056] In order to derive the optimal mixing ratio for wrinkle and elasticity improvement and skin regeneration using the above compositions, each composition was configured as shown in Table 1 below based on 1cc of the injectable composition.

[0057] Example 1 Example 2 Example 3 Example 4 Example 5 Comparative Example 1 Comparative Example 2 1 Hyaluronic Acid 0.6cc 0.6cc 0.6cc 0.6cc 0.6cc 0.4cc 0.75cc 2 Botulinum Toxin 6.6IU 6.6IU 6.6IU 6.6IU 6.6IU 6.6IU 3 Polydeoxyribonucleotide 0.05cc 0.05cc 0.06cc 0.07cc 0.1cc 0.12cc 0.05cc 4 Placenta Extract 0.05cc 0.05cc 0.06cc 0.07cc 0.1cc 0.12cc 0.05cc 5 Poly-d,l-lactic Acid 0.03cc 0.04cc 0.04cc 0.05cc 0.03cc 0.05cc 0.05cc 6 Adenosine 0.03cc 0.04cc 0.04cc 0.04cc --- 7 Epidermal Growth Factor 0.03cc 0.03cc 0.03cc ---- 8 Vitamin C (Ascorbic Acid) 0.02cc 0.02cc ----- 9 Tranexamic Acid 0.02cc ------ 10 Normal Seline Saline)0.17cc0.17cc0.17cc0.17cc0.17cc0.31cc0.1cc

[0058]

[0059] <Experimental Example 1> Evaluation of Wrinkle Improvement Effect (UVB-Induced Wrinkle Mouse Model)

[0060] To confirm the wrinkle-improving effect of the injectable composition of the present invention prepared in the preparation example, 4-week-old male SKH-1 mice were purchased, and skin wrinkles were induced by irradiating them with an ultraviolet B (UVB) light source (280-320 nm) at an intensity of 100 mJ / cm² three times a week for 8 weeks. Subsequently, 0.2 cc of the injectable composition of the present invention prepared in the preparation example was subcutaneously injected into the backs of each mouse. Physiological saline was injected as a control in the same manner.

[0061] The depth and length of the wrinkles were measured weekly for 8 weeks after injection using a 3D skin analyzer (PRIMOS®). In addition, after 8 weeks, mice were sacrificed and skin tissues were excised, and dermal thickness and collagen density were evaluated using H&E staining and Masson's trichrome staining. The experimental results are shown in Table 2 below.

[0062] Example 1 Example 2 Example 3 Example 4 Example 5 Comparative Example 1 Comparative Example 2 Control Group (Physiological Saline) Wrinkle Depth Reduction Rate (%) 28.5 24.2 19.4 16.1 14.3 7.2 7.8 3.5 Wrinkle Length Reduction Rate (%) 29.3 25.1 20.7 18.9 15.5 7.1 6.7 4.2 Dermal Thickness Increase Rate (%) 26.8 21.5 18.7 14.9 10.2 6.8 6.2 2.5 Collagen Density Increase Rate (%) 25.6 23.2 18.4 16.3 10.8 6.5 6.9 3.1

[0063]

[0064] As can be seen from the results in Table 2 above, the injectable compositions of Examples 1 and 2 showed the best effects in terms of reducing wrinkle depth and length, and increasing dermal thickness and collagen density. Specifically, Example 1 showed a reduction rate of 28.5% in wrinkle depth and 29.3% in wrinkle length, and an increase rate of 26.8% in dermal thickness and 25.6% in collagen density, while Example 2 showed a reduction effect of 24.2% in wrinkle depth and 25.1% in wrinkle length, and an increase effect of 21.5% in dermal thickness and 23.2% in collagen density. On the other hand, Comparative Examples 1 and 2 showed significantly lower wrinkle improvement effects than the compositions of the Examples.

[0065] As a result, the compositions of Example 1 and Example 2 showed excellent results in improving skin wrinkles, while Comparative Examples 1 and 2 showed results similar to the control group, indicating a negligible effect.

[0066] <Experimental Example 2> Evaluation of Skin Elasticity Improvement Effect (UVB-induced skin elasticity reduction model mouse)

[0067] To confirm the skin elasticity-improving effect of the injectable composition of the present invention prepared in the above preparation example, 4-week-old male HR-1 hairless mice were purchased and acclimatized for 1 week, after which a decrease in skin elasticity was induced by ultraviolet B (UVB) irradiation. UVB irradiation conditions were carried out three times a week at 120 mJ / cm² each time for 8 weeks. 0.2cc of the injectable composition of the present invention prepared in the preparation example was subcutaneously injected into the dorsal area of ​​the mice with induced decreased elasticity. Physiological saline was used as a control, and the procedure was carried out twice a week for 4 weeks.

[0068] After 4 weeks of treatment, dorsal skin samples were taken from mice to measure skin elasticity. Skin elasticity was measured using a cutometer, and the results are shown in Table 3 below.

[0069] Example 1 Example 2 Example 3 Example 4 Example 5 Comparative Example 1 Comparative Example 2 Control Group (Physiological Saline) Skin Elasticity Increase Rate (%) 25.2 21.5 15.7 12.9 11.3 6.8 6.9 5.1

[0070] As can be seen from the results in Table 3 above, the injectable compositions of Examples 1 and 2 showed the best effect in terms of increasing skin elasticity. Specifically, Example 1 showed an increase rate of 25.2% in skin elasticity, and Example 2 showed an increase rate of 21.5%. Comparative Examples 1 and 2 showed results similar to the control group, indicating a negligible effect.

[0071] As described above, specific embodiments of the present invention have been described in detail; however, those skilled in the art who understand the spirit of the present invention will be able to easily propose other inventions that are inferior or other embodiments included within the scope of the spirit of the present invention by adding, changing, or deleting other components within the same spirit. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention is defined by the claims set forth below rather than by the detailed description above, and all modifications or variations derived from the meaning and scope of the claims and equivalent concepts should be interpreted as being included within the scope of the present invention.

Claims

1. Hyaluronic acid, Botulinum toxin, Polydeoc An injectable composition for improving wrinkles, elasticity, and skin regeneration comprising polydeoxyribonucleotide, placenta extract, poly-d,l-lactic acid, and normal saline.

2. In Paragraph 1, The above composition is an injectable composition for improving elasticity and regenerating skin, further comprising adenosine, epidermal growth factor, and vitamin C (ascorbic acid) as active ingredients.

3. In Paragraph 1, The above composition is, An injectable composition for improving elasticity and regenerating skin, characterized by being prepared by mixing 0.5 to 0.7 cc of hyaluronic acid, 6 to 7 IU of botulinum toxin, 0.05 to 0.12 cc of polydeoxyribonucleotide, 0.05 to 0.12 cc of placenta extract, and 0.01 to 0.05 cc of poly-d,l-lactic acid with 0.1 to 0.2 cc of normal saline, based on 1 cc of the injectable composition.

4. In Paragraph 2, The above composition is, Based on 1cc of the injectable composition, 0.5 to 0.7cc of hyaluronic acid, An injectable composition for improving elasticity and regenerating skin, characterized by being prepared by mixing 6 to 7 IU of botulinum toxin, 005 to 012 cc of polydeoxyribonucleotide, 005 to 012 cc of placenta extract, 001 to 005 cc of poly-d,l-lactic acid, 001 to 005 cc of adenosine, 001 to 003 cc of epidermal growth factor, and 001 to 005 cc of vitamin C with 01 cc to 02 cc of normal saline.

5. In Paragraph 2, The above composition is an injectable composition for improving wrinkles, elasticity, and skin regeneration, further comprising tranexamic acid.